discovery of glp 1 Evolution GLP‐1 Receptor Agonists for Diabetes Treatment Reflections on the discovery GLP-1

Important safety considerations include contraindications in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, caution in those with a history of pancreatitis, increased risk of gallbladder disease, potential for acute kidney injury with dehydration, and possible worsening of diabetic retinopathy with rapid glycemic improvement

How They Work: The Biological Difference The reason topiramate is not a GLP-1 comes down to biology

Am J Physiol - Endocrinol Metab (2019) 316(4):E56877

Hadidchi will help you navigate the options and choose the most effective and safe therapy for your needs

Farxiga/Forxiga is not currently approved for weight loss as a standalone indication in non-diabetics, but the evidence is accumulating: Currently, if weight loss is the primary goal in a non-diabetic patient, GLP-1 agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) produce substantially greater weight loss (1015% vs 24%)

Have I verified FSA/HSA eligibility directly with my plan administrator